Epidemiology of Fontan-associated liver disease in Japan: Results from a nationwide survey in 2021

被引:4
|
作者
Ohfuji, Satoko [1 ,5 ]
Tanaka, Atsushi [2 ]
Kogiso, Tomomi [3 ]
Kanto, Tatsuya [4 ]
机构
[1] Osaka Metropolitan Univ, Grad Sch Med, Dept Publ Hlth, Osaka, Japan
[2] Teikyo Univ, Sch Med, Dept Med, Tokyo, Japan
[3] Tokyo Womens Med Univ, Dept Internal Med & Gastroenterol, Tokyo, Japan
[4] Natl Ctr Global Hlth & Med, Res Ctr Hepatitis & Immunol, Ichikawa, Japan
[5] Osaka Metropolitan Univ, Grad Sch Med, Dept Publ Hlth, 1-4-3 Asahi Machi,Abeno Ku, Osaka 5458585, Japan
关键词
cross-sectional study; incidence; predictor; prevalence; prognosis;
D O I
10.1111/hepr.14040
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
AimAlthough the Fontan procedure has improved the survival of patients with single-ventricle heart disease, the long-term consequences of the procedure have been a concern. This study aimed to explore the patients' postoperative clinical characteristics, including a diagnosis of Fontan-associated liver disease (FALD).MethodsA nationwide Japanese epidemiological survey of post-Fontan patients was undertaken in 2021. The survey targets were selected from all departments of pediatrics, pediatric surgery, cardiology, cardiovascular surgery, and gastroenterology using stratified random sampling by the number of beds. Each department was asked to complete a mail-back questionnaire on the numbers of patients and their clinical characteristics. The diagnosis of FALD was made by each attending physician.ResultsThe estimated number of post-Fontan patients was 7810 (95% confidence interval, 5430-10 200) in 2020, with a period prevalence of 61.9 per million. During the follow-up of 13.8 years after the Fontan procedure, 40% of patients were diagnosed with FALD. An elevated gamma-glutamyl transpeptidase level was the most common finding leading to the FALD diagnosis (41%), and 45% of the patients also showed liver fibrosis. Compared with non-FALD patients, FALD patients were older, had longer duration since the Fontan procedure, and had more severe cardiac or liver conditions. However, more than half of the non-FALD patients had elevated liver enzyme levels, suggesting underestimation of the number of FALD patients.ConclusionsIn 2020, approximately 40% of post-Fontan patients underwent follow-up with a diagnosis of FALD, although the lack of established diagnostic criteria for FALD could affect the reported prevalence of FALD. In Japan, the number of post-Fontan procedure patients was estimated to be 7810 in 2020, and 3120 (40%) of these patients were diagnosed with Fontan-associated liver disease (FALD) during the median follow-up of 13.8 years after the procedure. The most common sign leading to the diagnosis of FALD other than liver fibrosis was an elevated gamma-glutamyl transpeptidase level. More than half of the patients without a diagnosis of FALD had increased liver enzymes, suggesting that the number of patients with FALD was underestimated. image
引用
收藏
页码:931 / 941
页数:11
相关论文
共 50 条
  • [41] Severe Fontan-Associated Liver Disease and Its Association With Mortality
    Guerrero-Chalela, Carlos-Eduardo
    Therrien, Judith
    Grossman, Yoni
    Guo, Liming
    Liu, Aihua
    Marelli, Ariane
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2023, 12 (19):
  • [42] Impact of ursodeoxycholic acid treatment on Fontan-associated liver disease
    Kogiso, Tomomi
    Ogasawara, Yuri
    Taniai, Makiko
    Shimada, Eriko
    Inai, Kei
    Tokushige, Katsutoshi
    Nakai, Yousuke
    JOURNAL OF GASTROENTEROLOGY, 2025, 60 (02) : 210 - 221
  • [43] Fontan Conduit Stent-Angioplasty and Progression of Fontan-Associated Liver Disease
    Kavin, Umakanthan
    Shahrier, Aniqa
    Bandisode, Varsha M.
    Chowdhury, Shahryar M.
    Rhodes, John F.
    Gaydos, Stephanie S.
    PEDIATRIC CARDIOLOGY, 2025, 46 (02) : 372 - 378
  • [44] Fontan-Associated Liver Disease Screening, Management, and Transplant Considerations
    Emamaullee, Juliet
    Zaidi, Ali N.
    Schiano, Thomas
    Kahn, Jeffrey
    Valentino, Pamela L.
    Hofer, Ryan E.
    Taner, Timucin
    Wald, Joyce W.
    Olthoff, Kim M.
    Bucuvalas, John
    Fischer, Ryan
    CIRCULATION, 2020, 142 (06) : 591 - 604
  • [45] Non-invasive biomarkers of Fontan-associated liver disease
    Emamaullee, Juliet
    Khan, Sara
    Weaver, Carly
    Goldbeck, Cameron
    Yanni, George
    Kohli, Rohit
    Genyk, Yuri
    Zhou, Shengmei
    Shillingford, Nick
    Sullivan, Patrick M.
    Takao, Cheryl
    Detterich, Jon
    Kantor, Paul F.
    Cleveland, John D.
    Herrington, Cynthia
    Kumar, S. Ram
    Starnes, Vaughn
    Badran, Sarah
    Patel, Neil D.
    JHEP REPORTS, 2021, 3 (06)
  • [46] Epidemiology of idiopathic cardiomyopathy in Japan: results from a nationwide survey
    Miura, K
    Nakagawa, H
    Morikawa, Y
    Sasayama, S
    Matsumori, A
    Hasegawa, K
    Ohno, Y
    Tamakoshi, A
    Kawamura, T
    Inaba, Y
    HEART, 2002, 87 (02) : 126 - 130
  • [47] Epidemiology of Kawasaki disease in Japan, 2017-2018: results from the nationwide survey
    Ae, Ryusuke
    Makino, Nobuko
    Kosami, Koki
    Matsubara, Yuri
    Nakamura, Yosikazu
    INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 2021, 50 : 6 - +
  • [48] Screening for Fontan-associated liver disease: are we doing enough?
    Tsoi, V.
    Mitropoulou, P.
    Chatterjee, K.
    Lwin, M.
    Salmon, A.
    Smith, L.
    Fitzsimmons, S.
    Kyi, N.
    Carroll, A.
    EUROPEAN HEART JOURNAL, 2021, 42 : 1888 - 1888
  • [49] Fontan-Associated Liver Disease: Evidence for Early Surveillance of Liver Health in Pediatric Fontan Patients
    Rathgeber, Steven L.
    Harris, Kevin C.
    CANADIAN JOURNAL OF CARDIOLOGY, 2019, 35 (02) : 217 - 220
  • [50] SCREENING FOR AND MONITORING FONTAN-ASSOCIATED LIVER DISEASE IN A TERTIARY CENTRE
    Mitropoulou, Panagiota
    Carroll, Aisling
    Fitzsimmons, Samantha
    Smith, Lindsay
    Ramgopal, Balasubramanian
    Kyi, Nang
    HEART, 2023, 109 : A19 - A21